Table 3.
Biochemical, clinical, and endoscopic evaluations of patients in different cohorts.
| Variables | Patients with q8w/q4w SC (n = 105) | Patients with IV reinduction (n = 23) | p value |
|---|---|---|---|
| CRP normalization, n/n (%) | 53/105 (50.5) | 13/23 (56.5) | 0.599 |
| Clinical response, n/n (%) | 67/105 (63.8) | 18/23 (78.3) | 0.184 |
| Clinical remission, n/n (%) | 66/105 (62.9) | 16/23 (69.6) | 0.544 |
| Endoscopic response, n/n (%) | 32/72 (44.4) | 12/22 (54.5) | 0.406 |
| Endoscopic remission, n/n (%) | 16/72 (22.2) | 7/22 (31.8) | 0.360 |
CRP, C-reactive protein; IV, intravenous; q8/4w, every 8/4 weeks; SC, subcutaneous; UST: ustekinumab.